Export financials
MiMedx Group (MDXG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

MiMedx Group Cash Flow 2025-2009 | MDXG
Brief overview of MiMedx Group's cash movements
The comparison covers five available annual reports between 2021 and 2025.
Operating cash flow recovered from negative territory and reached $74 million. Core operations returned to generating cash.
Positive cash generation persisted in 3 of five years, so stability is not unconditional.
Operating cash flow covered cumulative profit by 1.35x, providing strong cash confirmation.
Cash from operations as a share of revenue increased from -0.8% to 17.7%, improving cash efficiency.
Working capital grew $42.2 million, or 10.1% of sales. Part of cash generation funded day-to-day operations.
What the cash flows show
MiMedx Group's cash flows are broadly resilient, though selected ratios need monitoring. Positive earnings conversion and moderate investment demand remain important.
Annual Cash Flow MiMedx Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
74 M | 66.2 M | 26.8 M | -17.9 M | -1.98 M | -30.3 M | -39.4 M | 35.8 M | 62.9 M | 23.8 M | 18.8 M | 16.8 M | -284 K | -3.33 M | -6.66 M | -8.16 M | - |
Depreciation & Amortization |
14.9 M | 6.04 M | 3.43 M | 3.34 M | 4.36 M | 5.78 M | 6.55 M | 5.88 M | 4.09 M | 3.33 M | 1.8 M | 1.2 M | 637 K | 465 K | 447 K | 444 K | - |
Accounts Payables |
14.5 M | 7.41 M | 9.05 M | 8.45 M | 7.38 M | 8.76 M | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
75.7 M | 55.8 M | 53.9 M | 43.1 M | 40.4 M | 35.4 M | 32.3 M | 51 M | 64.8 M | 67.2 M | 53.8 M | 26.7 M | 16.1 M | 7.65 M | 1.89 M | 162 K | - |
Total Inventories |
25.3 M | 23.8 M | 21 M | 13.2 M | 11.4 M | 10.4 M | 9.1 M | 16 M | - | 17.8 M | 7.46 M | 5.13 M | 3.88 M | 3.02 M | 713 K | 112 K | - |
All numbers in USD currency
Quarterly Cash Flow MiMedx Group
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-8.14 M | 1.88 M | - | 49 M | - | 5.3 M | - | - | - | 5.98 M | - | - | - | -4.05 M | - | -12.3 M | - | -10.2 M | - | 1.25 M | - | -6.68 M | - | -20 M | -15.4 M | -12.3 M | - | -16.3 M | -13.1 M | -15.3 M | - | 34.3 M | 30.9 M | 10.2 M | - | - | - | 10.6 M | - | 9.15 M | 6.3 M | -977 K | - | 14.5 M | 7.14 M | 4.21 M | - | 8.52 M | -432 K | -1.61 M | - | -1.12 M | -2.85 M | -2.1 M | - | -2.46 M | -1.6 M | -1.29 M | - | -5.01 M | -3.92 M | -1.79 M |
Depreciation & Amortization |
441 K | 528 K | - | 572 K | 558 K | 558 K | - | 192 K | 558 K | 558 K | - | 190 K | 191 K | 714 K | - | 831 K | 858 K | 860 K | - | 923 K | 1.31 M | 1.16 M | - | 1.57 M | 1.42 M | 1.51 M | - | 1.64 M | 1.6 M | 1.7 M | - | 1.4 M | 1.3 M | 1.22 M | - | 1.01 M | 1.12 M | 946 K | - | 838 K | 821 K | 734 K | - | 470 K | 422 K | 354 K | - | 313 K | 288 K | 263 K | - | 185 K | 139 K | 98.8 K | - | 354 K | 231 K | 110 K | - | 331 K | 232 K | 116 K |
Accounts Payables |
8.29 M | 11.5 M | 14.5 M | 11.4 M | 8.5 M | 8.87 M | 7.41 M | 6.92 M | 7.6 M | 9.7 M | 9.05 M | 9.17 M | 8.15 M | 7.82 M | 8.85 M | 8.82 M | - | 8.12 M | 7.38 M | 6.88 M | 10.6 M | 6.92 M | 8.76 M | 8.76 M | 8.76 M | 8.76 M | 8.71 M | 8.71 M | 8.71 M | 10.7 M | 14.9 M | - | 14.9 M | 14.9 M | - | 8.77 M | 11.5 M | 10.9 M | 11.4 M | 11.2 M | 11.4 M | 11.4 M | 6.63 M | 7.24 M | 6.63 M | 6.63 M | 3.66 M | 2.76 M | 3.66 M | 3.66 M | 2.49 M | 2.21 M | 2.49 M | 2.49 M | 1.25 M | - | 1.25 M | 1.25 M | - | - | - | - |
Accounts Receivables |
41.3 M | 46 M | 75.7 M | 78.2 M | 69.2 M | 62.3 M | 55.8 M | 54 M | 52.8 M | 57 M | 53.9 M | 49 M | 49 M | 44.7 M | 43.1 M | 40.8 M | - | 37.7 M | 40.4 M | 36.5 M | 37.2 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 32.3 M | 32.3 M | 32.3 M | 32.3 M | 51 M | - | - | - | 64.8 M | 59.6 M | 60.7 M | 66.8 M | 1.93 M | 67.2 M | 67.2 M | 67.2 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 26.7 M | 26.7 M | 26.7 M | 26.7 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 1.89 M | 1.89 M | 1.89 M | 1.89 M |
Total Inventories |
20.9 M | 26.2 M | 25.3 M | 26.5 M | 24.9 M | 24.1 M | 23.8 M | 24.2 M | 25.1 M | 24.5 M | 21 M | 19.1 M | 16.8 M | 14.7 M | 13.2 M | 14 M | - | 13.2 M | 11.4 M | 11.2 M | 10.1 M | 11.6 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 16 M | - | 16 M | 16 M | 9.47 M | 10.4 M | 15 M | 16 M | 15.9 M | 17.8 M | 17.8 M | 17.8 M | 7.46 M | 7.46 M | 7.46 M | 7.46 M | 5.13 M | 5.13 M | 5.13 M | 5.13 M | 3.88 M | 3.88 M | 3.88 M | 3.88 M | 3.02 M | 3.02 M | 3.02 M | 3.02 M | 713 K | 713 K | 713 K | 713 K |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company MiMedx Group, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
$ 64.0 | 7.26 % | $ 9.72 B | ||
|
Boston Scientific Corporation
BSX
|
$ 44.68 | 0.06 % | $ 66.1 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 8.7 | 0.06 % | $ 634 M | ||
|
ClearPoint Neuro
CLPT
|
$ 14.61 | 13.03 % | $ 414 M | ||
|
CONMED Corporation
CNMD
|
$ 45.18 | 3.31 % | $ 1.4 B | ||
|
Cytosorbents Corporation
CTSO
|
$ 4.3 | 1.63 % | $ 268 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Delcath Systems
DCTH
|
$ 16.08 | 0.75 % | $ 576 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Electromed
ELMD
|
$ 27.86 | 1.05 % | $ 230 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 65.58 | 3.69 % | $ 1.94 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 85.73 | 0.32 % | $ 50.1 B | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 5.57 | 0.43 % | $ 753 M | ||
|
Helius Medical Technologies
HSDT
|
$ 2.9 | 0.69 % | $ 63.9 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 15.88 | 2.25 % | $ 1.22 B | ||
|
Inogen
INGN
|
$ 5.23 | 2.75 % | $ 139 M | ||
|
InMode Ltd.
INMD
|
$ 14.19 | 0.21 % | $ 917 M | ||
|
Inspire Medical Systems
INSP
|
$ 68.81 | 0.59 % | $ 2.02 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.51 % | $ 10.7 M | ||
|
IRadimed Corporation
IRMD
|
$ 85.2 | 0.08 % | $ 1.08 B | ||
|
AxoGen
AXGN
|
$ 43.32 | 0.48 % | $ 1.99 B | ||
|
Align Technology
ALGN
|
$ 145.63 | 4.36 % | $ 10.6 B | ||
|
LENSAR
LNSR
|
$ 7.08 | 0.28 % | $ 84.7 M | ||
|
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | ||
|
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | ||
|
Medtronic PLC
MDT
|
$ 88.51 | 0.32 % | $ 113 B | ||
|
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | ||
|
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | ||
|
Myomo
MYO
|
$ 1.67 | 1.83 % | $ 69.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.66 | 0.45 % | $ 42.8 M | ||
|
InspireMD
NSPR
|
$ 0.7 | 0.37 % | $ 45 M | ||
|
Orthofix Medical
OFIX
|
$ 9.16 | 0.11 % | $ 363 M | ||
|
Outset Medical
OM
|
$ 3.13 | 1.29 % | $ 47.6 K | ||
|
Insulet Corporation
PODD
|
$ 135.78 | 0.01 % | $ 9.55 B | ||
|
Profound Medical Corp.
PROF
|
$ 5.6 | 1.66 % | $ 169 M | ||
|
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.18 | 0.63 % | $ 136 M | ||
|
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | ||
|
AVITA Medical
RCEL
|
$ 11.58 | 5.75 % | $ 323 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Apyx Medical Corporation
APYX
|
$ 2.83 | 1.37 % | $ 116 M | ||
|
Sintx Technologies
SINT
|
$ 1.87 | 5.06 % | $ 5.19 M | ||
|
Accuray Incorporated
ARAY
|
$ 0.22 | 0.4 % | $ 27 M | ||
|
Smith & Nephew plc
SNN
|
$ 26.68 | 0.02 % | $ 23.1 B | ||
|
Inari Medical
NARI
|
- | - | $ 4.23 B |